MX2022011179A - Uso medico de daridorexant. - Google Patents

Uso medico de daridorexant.

Info

Publication number
MX2022011179A
MX2022011179A MX2022011179A MX2022011179A MX2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A
Authority
MX
Mexico
Prior art keywords
daridorexant
medical use
daytime
pharmaceutically acceptable
formula
Prior art date
Application number
MX2022011179A
Other languages
English (en)
Inventor
Guy Braunstein
Scott Pain
Dalma Seboek-Kinter
Cedric Vaillant
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2022011179A publication Critical patent/MX2022011179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a daridorexant: (ver Fórmula) Fórmula (I) o una sal farmacéuticamente aceptable del mismo, tal como especialmente la sal de ácido clorhídrico; para su uso en un método para tratar los trastornos del sueño, tales como especialmente insomnios, en donde el daridorexant mejora el rendimiento diurno, especialmente reduce la somnolencia diurna asociada al trastorno del sueño.
MX2022011179A 2020-04-19 2021-04-16 Uso medico de daridorexant. MX2022011179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020060940 2020-04-19
PCT/EP2021/059943 WO2021213923A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Publications (1)

Publication Number Publication Date
MX2022011179A true MX2022011179A (es) 2022-10-07

Family

ID=75478068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011179A MX2022011179A (es) 2020-04-19 2021-04-16 Uso medico de daridorexant.

Country Status (13)

Country Link
US (1) US20230134935A1 (es)
EP (1) EP4138822A1 (es)
JP (1) JP2023521492A (es)
KR (1) KR20230004670A (es)
CN (1) CN115427037A (es)
AU (1) AU2021260018A1 (es)
BR (1) BR112022020924A2 (es)
CA (1) CA3175369A1 (es)
CL (1) CL2022002855A1 (es)
IL (1) IL297234A (es)
MX (1) MX2022011179A (es)
TW (1) TW202200133A (es)
WO (1) WO2021213923A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
MY179605A (en) 2013-12-04 2020-11-11 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
MX2017004950A (es) 2014-10-23 2018-01-16 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
CA3059394C (en) 2017-05-03 2023-09-12 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives

Also Published As

Publication number Publication date
BR112022020924A2 (pt) 2023-02-14
JP2023521492A (ja) 2023-05-24
IL297234A (en) 2022-12-01
KR20230004670A (ko) 2023-01-06
CL2022002855A1 (es) 2023-06-02
WO2021213923A1 (en) 2021-10-28
CN115427037A (zh) 2022-12-02
US20230134935A1 (en) 2023-05-04
AU2021260018A1 (en) 2022-12-22
CA3175369A1 (en) 2021-10-28
EP4138822A1 (en) 2023-03-01
TW202200133A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2022011179A (es) Uso medico de daridorexant.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
CA2793138C (en) Hydroxybenzoate salts of metanicotine compounds
MX2011013016A (es) Derivados de aminopirrolidinona y usos de los mismos.
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
JOP20190008A1 (ar) علاج ومنع اضطرابات النوم
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2022000143A (es) Metodos novedosos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
MX2023014530A (es) Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.